Calliditas Therapeutics (CALT)
(Real Time Quote from BATS)
$40.27 USD
-0.24 (-0.59%)
Updated Aug 28, 2024 01:18 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for Calliditas Therapeutics AB Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 114 | 80 | 27 | 0 | 20 |
Cost Of Goods | 6 | 2 | 0 | 0 | 0 |
Gross Profit | 108 | 78 | 27 | 0 | 20 |
Selling & Adminstrative & Depr. & Amort Expenses | 143 | 120 | 88 | 41 | 23 |
Income After Depreciation & Amortization | -35 | -42 | -61 | -41 | -3 |
Non-Operating Income | 3 | 5 | 2 | 0 | 0 |
Interest Expense | 11 | 4 | 1 | 6 | 1 |
Pretax Income | -43 | -41 | -60 | -48 | -3 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | -1 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -44 | -41 | -59 | -48 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -44 | -41 | -58 | -47 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -42 | -61 | -41 | -3 |
Depreciation & Amortization (Cash Flow) | 5 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -35 | -42 | -61 | -41 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.82 | 26.50 | 25.42 | 22.44 | 18.51 |
Diluted EPS Before Non-Recurring Items | -1.64 | -1.54 | -2.29 | -2.11 | -0.19 |
Diluted Net EPS (GAAP) | -1.64 | -1.54 | -2.29 | -2.11 | -0.19 |
Fiscal Year end for Calliditas Therapeutics AB Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 52.28 | 28.40 | 42.68 | 27.25 | 25.59 |
Cost Of Goods | 4.99 | 1.35 | 2.11 | 1.38 | 1.35 |
Gross Profit | 47.29 | 27.05 | 40.57 | 25.87 | 24.24 |
SG&A, R&D, and Dept/Amort Expenses | 50.23 | 46.63 | 36.63 | 40.63 | 31.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.94 | -19.58 | 3.94 | -14.76 | -7.14 |
Non-Operating Income | 0.00 | 0.00 | 5.53 | -0.42 | 0.43 |
Interest Expense | 1.04 | 4.18 | 10.78 | 0.00 | 0.00 |
Pretax Income | -3.98 | -23.77 | -1.32 | -15.18 | -6.71 |
Income Taxes | 0.45 | -0.11 | 0.41 | 0.40 | 2.02 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.43 | -23.66 | -1.73 | -15.57 | -8.73 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.43 | -23.66 | -1.73 | -15.57 | -8.73 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 26.84 | 26.82 | 27.01 | 26.81 | 26.88 |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.88 | -0.06 | -0.58 | -0.33 |
Diluted Net EPS (GAAP) | -0.16 | -0.88 | -0.07 | -0.58 | -0.32 |